Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting SHP2 Cryptic Allosteric Sites for Effective Cancer Therapy.

International journal of molecular sciences - 4 Jun 2024

Rehman Ashfaq Ur, Zhao Cizhang, Wu Yongxian, Zhu Qiang, Luo Ray

Abstract excerpt

SHP2, a pivotal component downstream of both receptor and non-receptor tyrosine kinases, has been underscored in the progression of various human cancers and neurodevelopmental disorders. Allosteric inhibitors have been proposed to regulate its autoinhibition. However, oncogenic mutations, such as E76K, convert SHP2 into its open state, wherein the catalytic cleft becomes fully exposed to its ligands. This study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Allosteric Regulation
Share to Allosteric Site
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Binding Sites

Share to Molecular Dynamics Simulation

Share to Neoplasms

Share to Protein Binding

Share to Protein Tyrosine Phosphatase, Non-Receptor Type 11

Source

Open in PubMed Open full text

Identifiers

PMID: 38892388
DOI: 10.3390/ijms25116201
PMCID: PMC11172685

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting SHP2 Cryptic Allosteric Sites for Effective Cancer Therapy.PMID 38892388Read ↗

Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application.Semantic proximity Read ↗

Allosteric Inhibitors of SHP2: An Updated Patent Review (2015-2020).Semantic proximity Read ↗

An allosteric interaction controls the activation mechanism of SHP2 tyrosine phosphatase.Semantic proximity Read ↗

An allosteric interaction controls the activation mechanism of SHP2 tyrosine phosphataseSemantic proximity Read ↗

The pathogenic T42A mutation in SHP2 rewires the interaction specificity of its N-terminal regulatory domainSemantic proximity Read ↗

A novel partially open state of SHP2 points to a "multiple gear" regulation mechanism.Semantic proximity Read ↗

The Landscape of Protein Tyrosine Phosphatase (Shp2) and CancerSemantic proximity Read ↗

Inhibition of SHP2 as an approach to block RAS-driven cancers.Semantic proximity Read ↗

Cancer-Causing Mutations Alter the Interplay Between Loop Dynamics and Catalysis in the Protein Tyrosine Phosphatases SHP-1 and SHP-2Semantic proximity Read ↗

The pathogenic T42A mutation in SHP2 rewires the interaction specificity of its N-terminal regulatory domain.Semantic proximity Read ↗

Therapeutic potential of targeting SHP2 in human developmental disorders and cancers.Semantic proximity Read ↗

A hotspot phosphorylation site on SHP2 drives oncoprotein activation and drug resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.